Published in Protein Sci on April 01, 2010
Cellular strategies of protein quality control. Cold Spring Harb Perspect Biol (2011) 1.74
The mammalian disaggregase machinery: Hsp110 synergizes with Hsp70 and Hsp40 to catalyze protein disaggregation and reactivation in a cell-free system. PLoS One (2011) 1.74
Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases. Nat Rev Drug Discov (2011) 1.71
Metazoan Hsp70 machines use Hsp110 to power protein disaggregation. EMBO J (2012) 1.62
Protein rescue from aggregates by powerful molecular chaperone machines. Nat Rev Mol Cell Biol (2013) 1.31
Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils. J Am Chem Soc (2013) 1.15
Cellular strategies for regulating functional and nonfunctional protein aggregation. Cell Rep (2012) 1.08
Chaperone-mediated hierarchical control in targeting misfolded proteins to aggresomes. Mol Biol Cell (2011) 1.06
Human Hsp70 Disaggregase Reverses Parkinson's-Linked α-Synuclein Amyloid Fibrils. Mol Cell (2015) 1.03
Protein folding: The dark side of proteins. Nature (2010) 0.97
Surface adsorption considerations when working with amyloid fibrils in multiwell plates and Eppendorf tubes. Protein Sci (2013) 0.86
Spatial protein quality control and the evolution of lineage-specific ageing. Philos Trans R Soc Lond B Biol Sci (2011) 0.85
Extraneural manifestations of prion infection in GPI-anchorless transgenic mice. Virology (2011) 0.85
Mechanism of an ATP-independent protein disaggregase: II. distinct molecular interactions drive multiple steps during aggregate disassembly. J Biol Chem (2013) 0.78
Life cycle of cytosolic prions. Prion (2013) 0.77
Immunoprecipitation of amyloid fibrils by the use of an antibody that recognizes a generic epitope common to amyloid fibrils. PLoS One (2014) 0.75
Human cyclophilin 40 unravels neurotoxic amyloids. PLoS Biol (2017) 0.75
Prions. Proc Natl Acad Sci U S A (1998) 27.80
Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem (2006) 22.87
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol (2007) 17.69
Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A (1998) 16.04
Adapting proteostasis for disease intervention. Science (2008) 13.22
Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature (2002) 10.81
A beta oligomers - a decade of discovery. J Neurochem (2007) 8.88
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell (2005) 8.40
Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science (2001) 6.15
Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol (1999) 5.89
Opposing activities protect against age-onset proteotoxicity. Science (2006) 5.85
Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem (2002) 5.63
Folding proteins in fatal ways. Nature (2003) 5.58
Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem (2009) 5.23
Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med (Berl) (2003) 5.15
Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol (2000) 4.76
Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol (2004) 4.63
Therapeutic approaches to protein-misfolding diseases. Nature (2003) 4.57
Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron (1997) 4.49
The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc Natl Acad Sci U S A (2002) 4.25
Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry (2000) 3.62
Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging (2004) 3.13
The biological and chemical basis for tissue-selective amyloid disease. Cell (2005) 2.76
Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science (2003) 2.63
A causative link between the structure of aberrant protein oligomers and their toxicity. Nat Chem Biol (2010) 2.48
Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res (2005) 2.25
Chaperonin TRiC promotes the assembly of polyQ expansion proteins into nontoxic oligomers. Mol Cell (2006) 2.16
Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum Mol Genet (2007) 1.95
Trans-suppression of misfolding in an amyloid disease. Science (2001) 1.88
Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein. Proc Natl Acad Sci U S A (1992) 1.85
Pharmacological prevention of Parkinson disease in Drosophila. Nat Med (2002) 1.84
Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed beta-amyloid in neurons. J Neurosci (2004) 1.53
Furin initiates gelsolin familial amyloidosis in the Golgi through a defect in Ca(2+) stabilization. EMBO J (2001) 1.52
Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB J (2002) 1.48
Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid (2006) 1.34
Oxidative metabolites accelerate Alzheimer's amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation. Biochemistry (2005) 1.26
Oligomerization and toxicity of beta-amyloid-42 implicated in Alzheimer's disease. Biochem Biophys Res Commun (2000) 1.20
Stress, aging, and neurodegenerative disease. N Engl J Med (2006) 1.18
Site-specific modification of Alzheimer's peptides by cholesterol oxidation products enhances aggregation energetics and neurotoxicity. Proc Natl Acad Sci U S A (2009) 1.04
Metalloendoprotease cleavage triggers gelsolin amyloidogenesis. EMBO J (2005) 1.00
A kinetic assessment of the C. elegans amyloid disaggregation activity enables uncoupling of disassembly and proteolysis. Protein Sci (2009) 0.98
Secretion of amyloidogenic gelsolin progressively compromises protein homeostasis leading to the intracellular aggregation of proteins. Proc Natl Acad Sci U S A (2009) 0.96
Transgenic mouse models of neurodegenerative disease: opportunities for therapeutic development. Curr Neurol Neurosci Rep (2002) 0.94
A general strategy for the bacterial expression of amyloidogenic peptides using BCL-XL-1/2 fusions. Protein Sci (2009) 0.81
Adapting proteostasis for disease intervention. Science (2008) 13.22
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
Opposing activities protect against age-onset proteotoxicity. Science (2006) 5.85
Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem (2009) 5.23
Semen-derived amyloid fibrils drastically enhance HIV infection. Cell (2007) 5.23
Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell (2006) 5.01
Therapeutic approaches to protein-misfolding diseases. Nature (2003) 4.57
Functional amyloid--from bacteria to humans. Trends Biochem Sci (2007) 4.50
Functional amyloid formation within mammalian tissue. PLoS Biol (2006) 3.92
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology (2012) 3.48
Structural basis for cargo regulation of COPII coat assembly. Cell (2008) 3.15
Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell (2008) 3.11
Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell (2009) 2.87
The biological and chemical basis for tissue-selective amyloid disease. Cell (2005) 2.76
Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci U S A (2002) 2.71
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol (2009) 2.70
Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science (2003) 2.63
Structure of the Sec13/31 COPII coat cage. Nature (2006) 2.63
An experimental survey of the transition between two-state and downhill protein folding scenarios. Proc Natl Acad Sci U S A (2008) 2.57
Context-dependent contributions of backbone hydrogen bonding to beta-sheet folding energetics. Nature (2004) 2.44
Structure-function-folding relationship in a WW domain. Proc Natl Acad Sci U S A (2006) 2.28
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A (2012) 2.27
Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res (2005) 2.25
Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc Natl Acad Sci U S A (2002) 2.25
Chemical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants. ACS Chem Biol (2006) 2.25
Domain interdependence in the biosynthetic assembly of CFTR. J Mol Biol (2006) 2.17
Tuning the free-energy landscape of a WW domain by temperature, mutation, and truncation. Proc Natl Acad Sci U S A (2003) 2.15
Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci U S A (2004) 2.14
Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry (2004) 2.08
Amyloid-β forms fibrils by nucleated conformational conversion of oligomers. Nat Chem Biol (2011) 2.08
The COPII cage: unifying principles of vesicle coat assembly. Nat Rev Mol Cell Biol (2006) 1.88
Stress-independent activation of XBP1s and/or ATF6 reveals three functionally diverse ER proteostasis environments. Cell Rep (2013) 1.87
An adaptable standard for protein export from the endoplasmic reticulum. Cell (2007) 1.86
ALS mutants of human superoxide dismutase form fibrous aggregates via framework destabilization. J Mol Biol (2003) 1.82
Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity. Chem Biol (2004) 1.76
Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A (2013) 1.73
Determinants for dephosphorylation of the RNA polymerase II C-terminal domain by Scp1. Mol Cell (2006) 1.71
COPII-dependent export of cystic fibrosis transmembrane conductance regulator from the ER uses a di-acidic exit code. J Cell Biol (2004) 1.70
The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol (2012) 1.70
Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem Biol (2005) 1.68
Small-molecule proteostasis regulators for protein conformational diseases. Nat Chem Biol (2011) 1.64
Therapeutic strategies for human amyloid diseases. Nat Rev Drug Discov (2002) 1.63
Geranylgeranyl switching regulates GDI-Rab GTPase recycling. Structure (2003) 1.63
Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr Opin Struct Biol (2010) 1.62
Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity. Sci Transl Med (2011) 1.62
Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. Nat Chem Biol (2006) 1.60
Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention. J Med Chem (2007) 1.58
Metabolite-initiated protein misfolding may trigger Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 1.55
Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des (2008) 1.55
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol (2013) 1.54
Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem (2004) 1.54
The core trisaccharide of an N-linked glycoprotein intrinsically accelerates folding and enhances stability. Proc Natl Acad Sci U S A (2009) 1.54
Amylin proprotein processing generates progressively more amyloidogenic peptides that initially sample the helical state. Biochemistry (2008) 1.51
Diversity in the origins of proteostasis networks--a driver for protein function in evolution. Nat Rev Mol Cell Biol (2013) 1.51
Non-conventional trafficking of the cystic fibrosis transmembrane conductance regulator through the early secretory pathway. J Biol Chem (2002) 1.50
Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest (2004) 1.50
Engineering a beta-sheet protein toward the folding speed limit. J Phys Chem B (2005) 1.49
Large-scale profiling of Rab GTPase trafficking networks: the membrome. Mol Biol Cell (2005) 1.49
Structural design of cage and coat scaffolds that direct membrane traffic. Curr Opin Struct Biol (2007) 1.44
Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis. PLoS Biol (2008) 1.42
Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis. Cold Spring Harb Perspect Biol (2011) 1.41
Biological and structural basis for Aha1 regulation of Hsp90 ATPase activity in maintaining proteostasis in the human disease cystic fibrosis. Mol Biol Cell (2010) 1.41
A fundamental protein property, thermodynamic stability, revealed solely from large-scale measurements of protein function. Proc Natl Acad Sci U S A (2012) 1.39
Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action. Angew Chem Int Ed Engl (2003) 1.39
Localized thermodynamic coupling between hydrogen bonding and microenvironment polarity substantially stabilizes proteins. Nat Struct Mol Biol (2009) 1.37
D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? Biochemistry (2003) 1.36
Endogenous protein S-Nitrosylation in E. coli: regulation by OxyR. Science (2012) 1.34
Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid (2006) 1.34
Chemical and biological folding contribute to temperature-sensitive DeltaF508 CFTR trafficking. Traffic (2008) 1.34
The delta subunit of AP-3 is required for efficient transport of VSV-G from the trans-Golgi network to the cell surface. Proc Natl Acad Sci U S A (2002) 1.32
The pathway by which the tetrameric protein transthyretin dissociates. Biochemistry (2005) 1.32
The proteostasis boundary in misfolding diseases of membrane traffic. FEBS Lett (2009) 1.31
Heparin accelerates gelsolin amyloidogenesis. Biochemistry (2006) 1.31
Pharmacologic chaperoning as a strategy to treat Gaucher disease. FEBS J (2007) 1.29
N-terminal domains elicit formation of functional Pmel17 amyloid fibrils. J Biol Chem (2009) 1.28
Protein native-state stabilization by placing aromatic side chains in N-glycosylated reverse turns. Science (2011) 1.27
Oxidative metabolites accelerate Alzheimer's amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation. Biochemistry (2005) 1.26
Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities. Proc Natl Acad Sci U S A (2003) 1.26
Rab-alphaGDI activity is regulated by a Hsp90 chaperone complex. EMBO J (2002) 1.26
Toward assessing the position-dependent contributions of backbone hydrogen bonding to beta-sheet folding thermodynamics employing amide-to-ester perturbations. J Am Chem Soc (2004) 1.26
Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. Biochemistry (2008) 1.26
Endoplasmic reticulum Ca2+ increases enhance mutant glucocerebrosidase proteostasis. Nat Chem Biol (2010) 1.26
Toward quantification of protein backbone-backbone hydrogen bonding energies: An energetic analysis of an amide-to-ester mutation in an alpha-helix within a protein. Protein Sci (2008) 1.26
The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation. Biochemistry (2007) 1.25
Amyloid as a natural product. J Cell Biol (2003) 1.25
NMR solution structure of the isolated Apo Pin1 WW domain: comparison to the x-ray crystal structures of Pin1. Biopolymers (2002) 1.24